Clinical Trial

Sentinel Node Mapping in High Risk Endometrial Cancer

Study acronym: ALICE
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 30, 2024 (before its estimated December 20, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate the role of systematic lymphadenectomy after sentinel node (SLN) mapping in high risk endometrial cancer (high grade histologies or deep myometrial invasion). The participants will be randomized in a non-inferiority controlled trial in 2 groups: SLN mapping or SLN mapping followed by systematic lymphadenectomy.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT03366051
Lead Sponsor AC Camargo Cancer Center
Conditions Endometrial Cancer, Lymph Node Metastases
Enrollment 178 participants
Start Date 2017-12-22
Primary Completion 2024-12-20 (estimated)
Study Completion 2024-12-20 (estimated)
Updated on ClinicalTrials.gov 2024-07-30